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We investigated the impact of intrafractional prostate motion on radiation dose 
distributions to the whole prostate with boosts to a dominant intra-prostatic cancer lesion 
(DIL) from sequential boost plans (separate prostate and boost plans) and simultaneous 
boost plans (single prostate and boost plan).
Six treatment plans were generated for two patient CT scans. Plans were delivered 
and 2D dose distributions were measured on a phantom using a motion platform driven 
with typical prostate intrafractional motions.
The relative root mean square difference between measured dose with and 
without motion inside the DIL for the simultaneous plans (1.6%—2.1%) were lower than 
those for the sequential plans (4.5%-7.2%) and the total beam-on time was shorter. Dose 
escalation to DIL using simultaneous boost plans with sufficient margin around DIL (7 
mm) is feasible provided that severe prostate motion is infrequent ( < 5/35 fractions ).
Keywords: Intensity Modulated Radiation Therapy, Volumetric Modulated Arc Therapy, 
Dominant Intra-prostatic Lesion, Prostate Cancer, Prostate Intrafractional Motion.
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Cancer is the class of diseases in which a cell or a group of malignant mass of 
cells displays uncontrolled growth. Uncontrolled growth of cells is not lethal; it is the 
interference of the uncontrolled growth with the normal function of critical organs and 
act negatively on the survival of the subject [1]. Prostate cancer starts in the cells of the 
prostate gland and it is the most common cancer in Canadian men. In 2010 an estimated 
24,600 men will be diagnosed with prostate cancer and 4,300 will die of it [2].
There are three main techniques to treat prostate cancer. These techniques are 
surgery, chemotherapy and radiation therapy. Typically combinations of these techniques 
are used to maximize the chances of curing the patient. There are considerable side 
effects for each of these techniques; surgery involves the removal of the prostate which 
results in total loss of its functionality. Chemotherapy can result is serious side effect 
such as feeling nauseous, lack of energy and hair loss [3]. Radiation therapy side effects 
can include urological and rectal bleeding [4]. Unlike surgery and chemotherapy, with 
accurate and precise radiation treatment delivery some of these side effects can be 
avoided. Radiation therapy is the focus of this work.
1.2 Radiation Therapy
Radiation therapy is the clinical process that uses radiation in the treatment of 
cancer. This can be achieved by using ionizing radiation to control cancerous masses
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within the body. The aim of radiation therapy is to deliver a very accurate dose of 
radiation to a well-defined target volume with minimal damage to surrounding normal 
tissue, resulting in eradication of the disease, the prolongation of life and/or the 
improvement in the quality of life [5]. Radiation can be delivered in two ways, externally 
using a medical linear accelerator (external beam radiation therapy (EBRT)) or internally 
by implanting radioactive seeds surgically in an organ such as the prostate 
(Brachytherapy). The amount of radiation delivered to a target is expressed in units of 
Gray, Gy (J/kg).
1.2.1 The Linear Accelerator
Medical linear accelerators (LINACs) have become the predominant machine 
used in the treatment of cancer with ionizing radiation. LINACs provide electron beams 
with several electron energies (6, 9, 12, 16, 20 MeV) as well as photon beams with 
energies (6, 10, 18 MV) [6]. Simply the electrons, generated by an electron gun, are 
accelerated in a linear trajectory in a waveguide, then once they reach the head of the 
machine they follow a 270° trajectory using a bending magnet. As shown in Figure 1.1 
[6], the electron beam will travel through an ion-chamber and may follow one of two 
tracks, if an electron beam is to be used then the electron will hit a scattering foil and if a 
photon beam is to be used then the electrons will hit an X-ray target and bremsstrahlung 
photon radiation will be produced.
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Figure 1.1. A schematic diagram of the major components of a medical linear 
accelerator, (taken from Figure 3.11b of Podgorasak 2006 [6])
The beam then passes through a two stage collimating system, the first system is 
jaws and the second is the multileaf collimator (MLC). The jaws consist of two pairs of
blocks made of a high atomic number material such as lead to maximize attenuation. The 
jaws can shape the beam into square or rectangular shapes up to 40 cm wide. The MLC, 
shown in Figure 1.2, consists of a number of leaves (typically 120 and usually made of 
tungsten). Each leaf is controlled by an individual computer-controlled motor. The MLC 
provides a rapid way of creating an irregular field shapes.
Figure 1.2. An image showing a 120 
leaves MLC (adapted from VARIAN 




Intensity Modulated Radiotherapy (IMRT) is a treatment technique in which the 
incident photon beams are purposely modulated to achieve better dose conformality to 
the tumour and minimize dose delivered to the surrounding normal tissue. In IMRT the 
delivery is divided into multiple beams, each beam is delivered at a different gantry 
angle. The intensity can be altered by changing the MLC shape multiple times to create 
multiple segments for each beam [7], IMRT is inverse planned; the treatment goals and 
objectives are given to the treatment planning software, which will try to find the set of 
beam shapes and intensities that will achieve these goals.
1.2.3 VMAT
Volumetric Modulated Arc Therapy (VMAT) is recent treatment technique [8-9], 
In general, arc therapy is the type of radiation treatment that includes the delivery of 
radiation while the gantry is rotated around the patient. A VMAT plan usually consists of 
one or two arcs or more delivering continuous radiation to the patient. During delivery 
the gantry changes speed, the MLC changes shapes and the dose is delivered at different 
rates. VMAT is also inverse planned. One of the advantages of VMAT over IMRT is that 
the entrance dose to the patient gets distributed since the dose is delivered from all angles 
not just from 5 or 7 angles as in IMRT. Another advantage for VMAT is delivery time, in 
IMRT the gantry has to be moved to the new position for every beam and the system tests 
the new parameters for every beam. Unlike IMRT, VMAT is delivered in one setup and 
the system needs to test the parameters once only which improves the treatment time.
5
VMAT is a fairly new treatment technique and it has yet to be implemented 
clinically in many treatment facilities. It requires the implantation of new protocols and 
new quality assurance strategies.
1.2.4 Monitor Units and Control Points
A monitor unit (MU) is a measure of the machine output from a set of ion 
chambers in a linear accelerator in radiation therapy. Linear accelerators are calibrated 
such that 1 MU gives an absorbed dose of 1 cGy delivered in a water phantom at 5 cm 
depth on the central beam axis for both 6 an 18 MV when irradiated with a 10 x 10 cm2 
field at a source to surface distance (SSD) of 95 cm [10]. In general, the primary 
ionization chamber in the linear accelerator measures MUs, once the operator preset 
number of MUs has been reached, the primary ionization chamber circuitry shuts the 
LINAC down and terminates the dose delivery to the patient.
Control points (segments) represent points at which certain parameters for dose 
delivery are determined. These parameters include MLC positions and fractional MUs to 
be delivered at this particular MLC shape. For IMRT, each beam consists of several 
segments and during beam delivery the beam switches off after the delivery of the MUs 
assigned for that particular segment and the MLCs move to the new shape for the 
following segment and the beam is switched on again. This delivery concept is called 
step and shoot. As for VMAT, the arc is divided into angular control points. While the 
gantry is moving between control points the MLCs change shape and the fractional MUs 
assigned for the first control point is delivered. Once the delivery is over and the gantry is
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at the next control point, the MLCs will be at positions assigned for that particular control 
point.
1.3 Intrafractional Motion
Motion of the prostate during each fraction of EBRT is referred to as 
intrafractional motion. Example of intrafractional motion is lung motion (breathing) and 
prostate motion during treatment. For the prostate these variations depend on the bladder 
and rectum fillings [11], A study [12] provided continuous, real-time localization and 
monitoring of the prostate. The study reported different prostate motion patterns during 
the delivery of radiation therapy. Depending on the motion pattern, prostate can move 
anywhere between 1 to 15 mm. This can result in missing the tumour and increased 
irradiation of parts of the rectum and bladder.
1.4 Radiation Therapy treatment process
The process starts with the patient being diagnosed with cancer. The oncology 
team then decides on the treatment strategy to be implemented. If radiation therapy is the 
choice of treatment then the patient is sent for medical imaging to determine the location 
and size of the tumor [13]. Before the patient is treated, the radiation oncology team must 
make a decision on four inter-related factors: (1) goal of treatment outcome, (2) volume 
to be treated, (3) Radiation treatment technique and (4) dose to be delivered [14], The 
details of the process are described in the following subsections.
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1.4.1 Patient Imaging
A Computed Tomography (CT) scan is usually used for patient imaging. This is 
because CT provides electron density information which governs the probability of 
radiation interactions with the imaged structure. This can be accompanied by other 
imaging modalities such as magnetic resonance imaging (MRI), single photon emission 
computed tomography (SPECT) or positron emission tomography (PET). These 
techniques can be used to provide information not visualized using CT scans such as 
hypoxic regions within the affected area or better visualization of tumor and surrounding 
tissues.
1.4.2 Target Definition
The protocol that defines the treatment target is set laid out in the International 
Commission on Radiation Units Report (ICRU-62) [15]. It describes several target and 
critical structure volumes that are required for the treatment planning process and used 
for the plan evaluation. These volumes are contoured on the patient CT scans by a 
radiation oncologist. The principal volumes related to 3D treatment planning are the 
gross target volume (GTV), the clinical target volume (CTV), the internal target volume 
(ITV) and the planning target volume (PTV). Figure 1.3 shows the four volumes and how 
they are related to each other.
The GTV is defined as the visible extent of the malignant disease which is based 
on the information provided by different imaging modalities. The microscopic disease 
spread around the GTV that is invisible on the CT images can be accounted for by 
expanding the GTV into the CTV. The ITV consists of the CTV plus a margin and it
8
accounts for intrafractional motion resulting from organ motion during treatment. A setup 
margin is added to the ITV to create the PTV to account for setup uncertainties. If there is 
no ITV, the CTV is directly expanded to the PTV to account for both intrafractional 
motion and setup uncertainties.
Other organs that are in the vicinity of the CTV are contoured to ensure that they 
are not irradiated to levels that will induce toxicities. These organs are called organs at 
risk (OARs).
In the case of prostate cancer, the prostate is the CTV since the prostate will 
include both the gross and microscopic spread of the disease. The bladder, the rectum, 
and the femoral heads are considered OARs.
Figure 1.3. A diagram shows the four volumes of interest for 
treatment planning, the GTV, The CTV, the ITV and the PTV as set 
by the ICRU-62.
1.4.3 Treatment Planning
Once the target volumes and OARs are identified and delineated, the radiation 
oncology team uses set guidelines, protocols, and clinical experience to make a decision 
about the prescription dose and fractionation plan [13]. Since cancerous cells response to
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ionizing radiation is different from normal tissue cells, the dose is prescribed to be given 
in fractions, typically 2 Gy per fraction for 5 -  7 weeks [13].
A treatment planning system (TPS) is used to generate the treatment plan using 
the medical images and the contours created by the radiation oncologist. This is the stage 
were all the radiation treatment techniques are evaluated. Techniques include using 
multiple static beams that are planned in a forward or inverse manner to less common 
techniques like tomotherapy and arc therapy.
The treatment plan starts by choosing a plan isocenter, which is the point at which 
all the beams will intersect, and is usually the center of the target. The next step is to 
choose the photon energy. The depth of the maximum dose depends on the energy of the 
beam and is directly proportional to it. Figure 1.4 shows the depth-dose diagrams for 
photons [6], Once the photon energy is chosen, the number of beams, energy, beam 
angles and modifiers (if needed) are set. Field shapes and beam weights are chosen by the 
user (forward planning) or by the TPS during optimization (inverse planning), followed 
by dose calculation.
After the plan is generated, it is evaluated based on guidelines set by treatment 
protocols, certain radiation therapy oncology groups and patient-specific considerations. 
These guidelines provide the OARs normal tissue tolerances and the PTVs dose limits. 
For example, one of the constraints on prostate plans is for the PTV to receive at least 
95% of the prescribed dose for the plan to be considered acceptable [17]. Dose volume 
histograms (DVHs) represent a unique dose evaluation tool that is frequently used in 
radiation therapy [16].
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DVHs can be represented in two forms, differential and integrated. The 
differential DVH represents a histogram of the sum of the number of voxels with an 
average dose within a certain dose range and plots the resulting volume as a function of 
dose for a target structure or an OAR. An integrated DVH represents the fractional 
normalized volume receiving at least a dose D plotted against dose [10].
Figure 1.4. The depth-dose diagrams for photons, (taken from Figure 1.2 of 
Podgorasak 2006 [6])
1.4.4 Treatment Delivery
Once the treatment plan is generated, it will be imported to information 
management software to verify if the plan is compatible with the machine delivery 
constraints. Once the plan is verified and scheduled it will be tested for quality assurance 
(see section 1.4.5). The plan is delivered over many fractions and the total dose delivered 
is the accumulative dose delivered over the course of all the fractions. Uncertainties in 
the position and shape of the GTV are present at each fraction. These uncertainties can be
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due to interfraction effects (changes between treatment and planning) and intrafraction 
effects.
Interfraction effects result from day-to-day patient setup variations, variations in 
the filling of bladder and rectum, weight loss or gain and the reduction of the GTV 
volume as an outcome of the treatment. Expanding the CTV to PTV covers all of these 
uncertainties. A strategy that has been used is called image guided radiation therapy 
(IGRT). In this strategy the patient is imaged before the start of the radiation treatment on 
every fraction to account for temporary variations in the patients’ anatomy. The patient is 
then adjusted to minimize these variations [18].
1.4.5 Quality Assurance and Treatment Verification
To ensure that the LINAC is delivering accurate dose to the patient, daily, 
monthly, and yearly, machine-specific quality assurance tests must be performed. These 
tests include mechanical, operational, output and safety systems. These tests are outlined 
in documents such as AAPM TG-40 [19].
There are several tools to use for treatment patient-specific plan delivery 
verification. These tools involve films [20], diode arrays such as MapCheckIM (Sun 
Nuclear Corporation) [21] and ion chamber arrays such as the PTW 2D-Array Seven29 
[22]. Before a plan is delivered to a patient, one of these tools is used to verify the quality 
of the plan by comparing the measured dose in a plane to the same calculated dose on the 
same plane, a technique that is used to evaluate that is called the Gamma analysis 
technique.
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1.4.5.1 Gamma Analysis Technique
The Gamma analysis technique is a technique used for quantitative comparisons 
between measured and calculated dose distributions. Two thresholds are used as 
comparison parameters, the dose-difference (AD) and the distance-to-agreement (Ad). 
The thresholds represent tolerances in the error of the dose and distance to agreement in 
regions of low and high dose gradients, respectively.
For the dose difference criteria, difference between the measured and calculated 
doses are computed. The distance to agreement is the distance between a measured data 
point and the nearest point in the calculated dose distribution that exhibits the same dose. 
The dose difference and distance to agreement evaluations complement each other when 
used as determinants of dose distribution calculation quality [23].
The Gamma analysis technique simultaneously incorporates the dose and distance 
criteria. It provides a numerical quality index that serves as a measure of disagreement in 
the regions that fail the acceptance criteria and indicates the calculation quality in regions 
that pass. For a single measurement, the Gamma value is defined as
Y ( 0  =  { m in r (r OT,r c)} V { r c} (1)
where
(2)
Dm(rm) is the measured dose at position rm and Dc(rc) is the calculated dose at position rc. 
The does difference and distance to agreement criteria therefore become
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y(rm) < 1, if dose difference and distance to agreement are less than the respective 
thresholds,
y(rm) > 1, if dose difference and distance to agreement are less than the respective 
thresholds,
In the clinic, we accept a treatment plan when the difference from measurements yielded 
Y(rm) < 1 in at least 90% of the points.
1,4.6 Set-up Verification with IGRT
Before each treatment, patients are aligned on the LINAC couch using external 
marks (tattoos) made during their planning CT and room lasers. However, we can 
improve the setup and reduce the PTV margin if we can visualize patient’s internal 
anatomy and/or tumor. Pre-treatment imaging of the patient allows for the correction of 
these set-up errors.
It is currently possible to image patient anatomy just before delivery of a fraction 
of radiotherapy, thus gaining precise knowledge of the location of the target volume on a 
daily basis. This technique of dose delivery to the patient is known as IGRT and it 
ensures that the relative positions of the target volume and some reference point for each 
fraction are the same as in the treatment plan. This may allow reduced treatment margins, 
fewer complications, dose escalation and the avoidance of geographical misses. The ideal 
image guided system will allow the acquisition of soft tissue images at the time of each 
fraction of radiotherapy [10].
Several IGRT systems are currently commercially available. All systems allow 
pre-treatment imaging immediately after a patient is positioned on the LINAC treatment
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table for therapy. VARIAN IGRT system (VARIAN Medical Systems, Palo Alto, 
California, USA) is based on direct integration of a kilovoltage or/and megavoltage 
imaging system with an isocentric medical LINAC, allowing the acquisition of Cone 
Beam CT (CBCT)”. The kilovoltage system consists of a conventional X-ray tube 
mounted on a retractable arm at 90° to the high energy treatment beam and a flat panel X- 
ray detector mounted on a retractable arm opposite the X-ray tube [24],
kV CBCT imaging enables visualization of the tumour location just prior to 
patient treatment on a LINAC. The technique integrates CT imaging with a LINAC and 
involves acquiring multiple planar images produced by a kilovoltage cone beam rotating 
a 180° or 360° about the patient in the treatment position on the LINAC couch. The 
acquired data are then compared with the planning CT data and a decision is made on 
adjusting the patient position to account for tumour motion or set-up error.
l.S Motivation
Escalating the dose to the whole prostate can expose the bladder and rectum to 
dose that exceeds normal tissue tolerances. Enabling dose escalation to the dominant 
intraprostatic lesion (DIL) that requires a higher dose than the remainder of the prostate 
without exceeding normal tissue tolerances is a motivation of this study. With the 
advances in functional imaging technology identifying DIL is now possible [25-32].
However, intrafractional motion can affect the outcome of treatment considerably. 
With IGRT, intrafractional motion is minimized. Previous studies on dose escalation to a 
DIL involved treatment planning studies and delivery without considering the effect of 
intrafractional motion [33-36]. On the other hand, a number of studies have computer
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simulations investigating the impact of inter- and intra- fraction prostate motion on the 
dose distributions [37-40], Investigating the effect of intrafractional motion on the 
delivery of the generated treatment plans is a second motivation for this study.
1.6 Hypothesis
The hypothesis of this thesis is as follows: “there exists a dose escalation to a DIL 
treatment plan that is insensitive to prostate intrafractional motion”. This plan can be an 
IMRT plan or a VMAT plan or combination of both. The plan can be simultaneous (one 
plan) or sequential (two plans). Sequential plans are divided into a plan for the DIL and a 
plan for the prostate. We seek a plan that can be delivered with no intrafractional motion 
management and still have high chance in delivering the prescribed dose to 95% of the 
PTV. This would allow the treatment of prostate cancer patients minimizing the need to 
have real-time monitoring of the prostate motion during treatment. This is the first 
experimental phantom study that assesses the impact of prostate intrafractional motion on 
the delivery of different treatment plans.
1.7 Thesis Overview
This thesis is divided into three chapters. Chapter 1 is a general introduction to 
cancer and prostate cancer. It includes a general overview of the radiation therapy 
treatment process that covers the different radiation therapy treatment techniques used in 
this study. Chapter 2 is an adaptation of a manuscript that will be submitted to the 
Medical Physics journal. This work has been presented locally (London, Ontario, 
Canada) at the University of Western Ontario Department of Oncology Research and
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Education Day (June 2009 and 2010), CHIR Team Grant & OICR Imaging Pipeline 
Platform “Imaging Applications in Prostate Cancer” (November 2010) and at the 
American Association of Physicists in Medicine annual conference in Philadelphia, 
Pennsylvania, USA (July 2010). This chapter introduces an experiment that assesses the 
effect of the prostate intrafractional motion on the delivery of the dose escalation 
treatment plans to a DIL. Six treatment plans per patient were generated and delivered on 
a phantom with no motion applied. Six motion patterns were programmed on a 
commercial motion platform. The generated plans were then delivered to the phantom 
after the motion platform is set in motion. The measured data is analyzed and the results 
are compared for the different plans. This chapter includes more figures and more details 
than the submitted manuscript. Chapter 3 includes the discussion of the results listed in 
Chapter 2 in addition to the conclusions, limitations and future work.
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CHAPTER 2
Experimental assessments of intrafractional prostate motion on 
sequential and simultaneous boost to a dominant intra-prostatic lesion
This chapter is an adaptation of a manuscript to be submitted to Journal of 
Medical Physics in 2010, entitled “Experimental assessments of intrafractional prostate 
motion on sequential and simultaneous boost to a dominant intra-prostatic lesion” by Ady 
Abdellatif, Jeff Craig, Matt Mulligan, Homeira Mosalaei, Glenn Bauman, Jeff Chen, and 
Eugene Wong.
2.1 Introduction
Accurate delineation of tumour volume is crucial in external radiation therapy 
(EBRT) for optimal tumour control with minimum toxicities. The availability of 
functional imaging modalities such as Magnetic Resonance Imaging (MRI) spectroscopy 
[1-6], llC-Choline Positron Emission Tomography (PET) [7] and 18F-Choline PET [8] 
allowed better localization of Dominant Intraprostatic Lesions (DIL) for possible dose 
escalation to achieve better tumour control probability.
Several clinical studies [9-12] showed that dose escalation to the prostate 
improves tumor control. Several treatment planning studies on dose escalation to the 
prostate and to a dominant DIL were conducted previously. These studies included 
Intensity Modulated Radiation Therapy (IMRT) and Tomotherapy [13], simultaneous 
integrated IMRT boost [14] and Volumetric Modulated Arc Therapy (VMAT) [15]. A 
clinical study on 22 patients using IMRT was performed to assess the feasibility of
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escalating the dose to a DIL identified by magnetic resonance imaging (MRI) and 
magnetic resonance spectroscopy (MRS) [16].
Dose escalation to a very small volume of dominant intraprostatic lesion using 
IMRT or VMAT may be limited by uncertainties of DIL position during or between 
radiotherapy sessions. Breathing has little effect on intrafraction prostate motion if the 
patient is comfortable in the supine position [17, 18]. However, variations in the bladder 
and rectum filling contribute to inter and intra-fraction prostate motions [19]. These 
variations can result in prostate motion during EBRT while the patient is on the treatment 
couch (Intrafractional motion) or between different days of treatment (Interfractional 
motion). The variations can be accounted for by adding margins to the clinical target 
volume (CTV) if 3D conformal therapy is used. However, the inter-play effects of IMRT 
or VMAT [20-22] due to intra-fractional tumour motion can not be accounted for with 
margin. A study [23] using the Calypso 4D localization system (Calypso System, 
Calypso Medical, Seattle, WA, USA) provided continuous, real-time localization and 
monitoring of the prostate. The study reported different prostate motion patterns during 
the delivery of radiation therapy. While a number of studies have computer simulations 
investigating the impact of inter- and intra- prostate motion on the dose distributions [24- 
27], few had measured the delivered dose distributions that incorporated motion 
uncertainties.
In the present study, we compared a series of treatment plans delivered to a 
phantom with and without modeled prostate motions. The plans consisted of 76 Gy to the 
entire prostate with dose escalation to 86 Gy to a hypothetical DIL one eighth the size of 
the prostate, located in the posterior-inferior-left side of the prostate. The reason for
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choosing this DIL location is that many intraprostatic lesions are located near the rectal 
wall [28]. This comparison included sequential and simultaneous IMRT and VMAT 
boosts to the DIL. We investigated experimentally the impact of intrafractional prostate 
motion on the dose distributions of VMAT and IMRT boost plans to a DIL. This provides 
a more realistic comparison of treatment plans with dose escalation to the DIL including 
both plan delivery and motion uncertainties.
2.2 Methods and Materials
2.2.1 Treatment planning
A series of six treatment plans were generated for two patients CT scans using 
Pinnacle3 treatment planning system (Philips Medical, Andover, Massachusetts, USA) as 
listed in table 1. The prostate, the gross target volume (GTV), the rectum, the bladder and 
femoral heads were contoured by a radiation oncologist. Patient 1 (PI) had a larger 
prostate (72 cc) and rectum (65 cc) but a smaller bladder (110 cc). Patient 2 (P2) had a 
relatively smaller prostate (59 cc) and rectum (47 cc) but a larger bladder (201 cc). A 
hypothetical DIL, one eighth the size of the prostate, was contoured in the posterior- 
inferior-left side of the prostate (DILGTV). A 7 mm margin was added in all directions 
to the prostate GTV to create the prostate planning target volume (prostatePTV) and to 
the DIL GTV to create DILPTV to account for random and systematic uncertainties. 
The six plans generated for each patient were combinations of sequential and 
simultaneous boost using IMRT and VMAT. A dose of 86 Gy was prescribed to 
DIL PTV and 76 Gy to the prostate PTV in 35 fractions for all the plans. As a reference, 
IMRT and VMAT plans were also generated with a prescription of 86 Gy to the
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prostatePTV. The IMRT plans consisted of five beams at gantry angles 45°, 105°, 180°, 
255°, 315°. The VMAT plans included a single 360° dynamic arc. The IMRT 
simultaneous boost plan was generated with 18 MV photon energy and the VMAT 
simultaneous boost plan were generated with 6 MV photon energy and prescribed to be 
delivered in 35 fractions. All sequential plans were composed of a 5-field IMRT or 360° 
dynamic ARC plan with 10 Gy boost to the DILPTV delivered in either 5 or 35 
fractions and a second IMRT or ARC plan with 76 Gy prescribed to the prostate PTV 
delivered in 35 fractions. For all the sequential plans, the treatment is delivered in 35 
fractions. For the 5 fractions boost plans, the first five fractions will include the delivery 
of the boost and the prostate PTV plans and the remaining 30 fractions will consist of the 
delivery of the prostate PTV plan only. As for the 35 fractions boost plans, each fraction 
consists of a boost plan and a prostate PTV plan delivery. Table 2.1 lists all the plans that 
were generated and compared.
2.2.2 Plans evaluation and comparison
For a plan to be considered acceptable, at least 95% of the DIL PTV volume 
must receive a dose of 86 Gy and at least 95% of the prostate PTV must receive a dose 
of 76 Gy. Another criterion is that less than or equal to 2% of the DIL PTV volume 
should receive a maximum dose not exceeding 94.6 Gy. The guidelines set by the 
Radiation therapy Oncology Group (RTOG-0126) listed in Table 2.2 were used for dose
volume constraints of rectum and bladder.
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DIL PTV ProstatePTV
Plan 1 5 field IMRT (5 fx) 5 field IMRT (35 fx)
Plan 2 360° Dynamic ARC (5 fx) 360° Dynamic ARC (35 fx)
Plan 3 5 field IMRT (35 fx) 5 field IMRT (35 fx)
Plan 4 360° Dynamic ARC (35 fx) 360° Dynamic ARC (35 fx)
Plan 5 Simultaneous boost 5 field IMRT
Plan 6 Simultaneous boost 360° Dynamic ARC
Table 2.1. A list of the generated plans for both patient CT scans.
Organ At Risk Type Objective
Rectum Maximum relative volume 15%, 25%, 35%, and 50%
exceeding dose 75 Gy, 70 Gy,
65 Gy, and 60 Gy
Bladder Maximum relative volume 15%, 25%, 35%, and 50%
exceeding dose 80 Gy, 75 Gy,
70 Gy, and 65 Gy
Table 2.2. The rectum and bladder planning guidelines set by the Radiation therapy Oncology
Group (RTOG-0126).
Dose Volume Histograms (DVHs), dose distributions, minimum, maximum and 
mean dose of the DILPTV, rectum and bladder were used for plans comparison. Dose 
uniformity within the DIL PTV and dose spillage outside the prostatePTV were also 
used to evaluate the quality of a plan.
2.2.3 Plan delivery and dose measurements
2.2.3.1 Plan delivery
All plans were delivered on a VARIAN clinical linear accelerator (CLINAC iX) 
with RapidArc delivery capability (VARIAN Medical Systems, Palo Alto, California, 
USA). All generated plans were first imported to a record and verify system (ARIA, 
VARIAN oncology information management software). Delivered dose was measured 
using MapCHECKIM with MapPHAN™ (Sun Nuclear Corporation, Melbourne, Florida, 
USA). MapCHECK™ is a diode array that consists of 445 SunPoint Diode detectors 
distributed over a 20 x 20 cm grid. The detector spacing is 7.07 mm over the inner 10 x 
10 cm area and 14.04 mm over the outer 10 x 10 cm area. Absolute dose measured on 
diodes were compared to planned dose points using Gamma analysis method. 
MapPHAN™ is a homogeneous water equivalent phantom that holds MapCHECK™ at 
isocenter for rotational dosimetry. The MapCHECK ™-MapPHAN™ system can support 
measurements in the coronal and sagittal planes. 10 cm buildup was used for 
MapCHECKIM-MapPHAN™ system as shown in Figure 2.1.
All doses were measured using MapCHECK1 M-MapPHAN™ system set in the 
sagittal plane. The original plan on the patient CT is copied to the CT of MapCHECK™- 
MapPHAN1M system and the dose is calculated with the plan isocenter relocated to the 
center of the MapCHECK™-MapPHAN™ system. A planar dose of the plan is 





Figure 2.1. (a) The motion platform rotated by 40° on the treatment couch relative to the sagittal 
laser in the treatment room, (b) The MapCHECK™-MapPHAN™ system rotated by 90° 
counterclockwise around the sagittal laser in the sagittal plane and set on the rotated motion
platform.
2.2.3.2 Incorporation of prostate motion
A one dimensional programmable motion platform (QUASAR™ Programmable 
Respiratory Motion Platform, Modus Medical Devices, London, Ontario, Canada) was 
used for this experiment. The platform has dimensions of 35 x 35 cm and can hold a 
maximum weight of 20 kg. The platform can be operated manually or be controlled by 
programmable motion patterns. A clinical study [20] showed that there are 4 typical 
motion patterns. The study showed that the motion in the longitudinal (superior-inferior) 
and the vertical (anterior-posterior) directions are more prominent than the motion in the 
lateral (right-left) direction. It also showed that the longitudinal and vertical motions are 
correlated in all patterns. These 4 patterns were modeled and programmed into the 
motion platform software as shown in Figure 2.2. A 2 mm systematic shift in the 
amplitude of the motion platform was observed when the MapCHECK1 M-MapPHAN™
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Figure 2.2. Diagrams representing the programmed four motion patterns (a) temporary shift 
pattern (SI total extent from 0 to 9 mm -  AP total extent from 0 to 7 mm), (b) constant shift 
pattern (SI total extent from 0 to 8 mm -  AP total extent from 0 to 6 mm), (c) random motion 
pattern (SI total extent from -2 to 7 mm -  AP total extent from -2 to 8 mm), and (d) slow 
continuous drift pattern (SI total extent from 0 to -7 mm -  AP total extent from 0 to -7 mm).
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Since the motion platform is programmable only in one direction in the coronal 
plane and the intrafractional prostate motion is correlated in the longitudinal and vertical 
directions, an experimental method was improvised as follows. First, the MapCHECK™- 
MapPHAN™ system along with the beams in the patient CT plans were rotated by 90° 
(in the counterclockwise direction) about the gantry rotation axis. By performing this 
modification, we exchanged the vertical direction with the lateral and any motion in the 
lateral direction translates into motion in the vertical direction. Second, the motion 
platform is rotated by 40° on the treatment couch relative to the sagittal laser in the 
treatment room as shown in Figure 2.1a. Rotating the platform by 40° mimics the prostate 
longitudinal and vertical motions with approximately the same amount. An image of the 
setup of the motion platform and the MapCHECK -MapPHAN system is shown in 
Figure 2.1b. The four different prostate motion patterns, shown in Figure 2.2 are: (a) 
temporary shift; (b) constant shift; (c) random motion and (d) slow continuous drift. To 
investigate the sensitivity related to phase, these patterns were expanded to six by starting 
the temporary shift and the constant shift earlier: 50 s for the temporary shift (Pattern 5) 
and 78 s for the constant shift (Pattern 6). For the six motion patterns studied, the motion 
platform and beam delivery were simultaneously initiated.
The setup of the motion platform and the MapCHECK rM-MapPHAN™ system 
shown in Figure 2.1b was CT scanned. The rotated plan is then copied to the CT of the 
rotated motion platform and the MapCHECKrM-MapPHAN™ system and the dose is 
calculated. A planar dose is generated on the rotated “motion platform and the 
MapCHECK -MapPHAN system”. Plans were then delivered on the setup shown in 
Figure 2.1b. Each of the plans in Table 2.1 was delivered seven times: the first with a
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stationary system at the neutral position (“no-motion” pattern, Pattern 0) and six times 
with the platform moving according to the six motion patterns. Dose is recorded with 
MapCHECK1M for the 7 measurements for each of the 6 plans listed in Table 2.1 for two 
patients, resulting in 84 2D dose distributions for analyses.
2.2.3.3 Measurement evaluation
Gamma analysis was used to compare the seven measurements with the planar 
dose for each plan. The Gamma analysis threshold parameters used in this work are 3% 
percent in dose-difference and 3 mm for distance to agreement. In this particular case, 
Gamma value will be less than or equal to one if the dose difference is less than or equal 
to 3% or the distance-to-agreement is less than or equal to 3 mm. Without motion, at least 
90% of the compared points must pass the Gamma analysis criteria for a plan to be 
considered acceptable (i.e at least 90% of the points must have a Gamma value that is 
less than or equal to 1) [29]. The mean Gamma value was computed and compared for 
each motion pattern for each investigated plan.
Such Gamma analyses reflect dosimetric accuracies for a 2D plane of each plan. 
To assess dose delivered specifically to the DIL in the presence of motion, the relative 
root mean square (rrms) of the difference between the delivered dose for all the motion 
patterns and the delivered “no motion” dose inside a DIL (DIL GTV) volume is 
calculated and compared for all the plans for PI. The rrms is defined as
rrms =





where Dim is the measured dose for the z'th point inside the DILGTV contour for a 
certain motion pattern, Dinm is the measured dose for the corresponding point for the no 
motion pattern of the same plan, N  is the total number of measured dose points inside the 
DIL GTV contour and Dm is the average dose inside the DIL GTV for the no motion 
pattern. The rrms value measures the magnitude of the dose variation inside the 
DIL GTV, however these values do not provide information about the fraction of the 
DIL GTV receiving the prescribed dose. A method of measuring that is to calculate the 
percent of measured points receiving at least 90% of the prescribed dose inside the 
DILGTV.
To study the effect of motion for the whole treatment course, planar doses were 
accumulated according to the probability based on the Calypso data (Calypso System, 
Calypso Medical, Seattle, WA, USA) [20] in which 59% of the fractions exhibited no 
motion (Pattern 0), 26% of the fractions assumed motion between 3 - 5  mm (Patterns 1 
and 2) and 15% of the fractions assumed motion larger than 5 mm (Patterns 3, 4, 5 and 
6). For Plans 1 and 2, two combinations of patterns were used for comparison with three 
fractions covered by Pattern 0, one fraction by Pattern 1, and the last fraction covered 
alternatively by Patterns 6 (C5-1) and 3 (C5-2). The reason for choosing these two 
combinations is to cover the two extreme motion patterns. For the remaining four plans, 
four combinations of patterns were used to study the motion effect on the total treatment 
course: C35-1 to C35-4 as listed in Table 2.3. In addition to these combinations, an 
average combination was considered. In this combination, the mean Gamma value for 
each pattern was weighted according to its probability and an average Gamma value for
the whole treatment course was obtained.
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Combination Patterns
C35-1 (a) 21 fractions Pattern 0
(b) 9 fractions Pattern 1
(c) 5 fractions Pattern 6
C35-2 (a) 21 fractions Pattern 0
(b) 9 fractions Pattern 1
(c) 5 fractions Pattern 3
C35-3 (a) 21 fractions Pattern 0
(b) 5 fractions Pattern 1
(c) 4 fractions Pattern 2
(d) 3 fractions Pattern 3
(e) 1 fraction Pattern 4
(f) 1 fraction Pattern 5
C35-4 (a) 21 fractions Pattern 0
(b) 5 fractions Pattern 1
(c) 4 fractions Pattern 2
(d) 2 fractions Pattern 3
(e) 1 fraction Pattern 4
(f) 1 fraction Pattern 5
(g) 1 fraction Pattern 6
Table 2.3. The probability weighted combinations for the 35 fractions plans along with patterns




Figure 2.3 displays the dose distribution and the DVHs of ProstatePTV, rectum 
and bladder for the whole prostate dose escalation plans (IMRT and VMAT) for PI. In 
both plans the rectum and the bladder exceeded the RTOG 0126 guidelines. For example, 
more than 15% of the bladder volume exceeded 87 Gy for the IMRT plan and 88 Gy for 
the ARC plan respectively. Similarly, doses to 25% and 35% of bladder volumes were 
exceeded for both plans. As for the rectum more than 15% of its volume exceeded 80 Gy 
and 79 Gy for the IMRT plan and the ARC plan respectively. Similar results were 
obtained for P2.
Figure 2.4 shows the dose distribution and the DVHs (prostatePTV, DIL PTV, 
rectum and bladder) for the simultaneous IMRT and VMAT plans with 76 Gy to whole 
prostate and 10 Gy boost to DIL. Both plans met the constraints on the rectum and 
bladder while satisfying the prostate PTV and DIL PTV prescription objective. The dose 
distribution and the DVHs (prostate PTV, DIL PTV, rectum and bladder) for two 
sequential plans (Plan 1 and Plan 2 from Table 1) are shown in Figure 2.5. Table 2.4 lists 
the minimum, maximum and mean dose values for the DIL PTV and the Prostate PTV -  
DIL PTV. Similar results were observed for Plans 3 and 4 for PI and similar results were 





(a) IMRT (b) VMAT
Figure 2.3. A transverse slice dose distribution and DVHs for the rectum (blue), bladder (red) 
and the prostatePTV (green) for the whole prostate dose escalation to 86 Gy for PI. (a) IMRT
Plan, (b) VMAT plan.
i
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Dose Volume Histogram Dose Volume Histogram
(a) Simultaneous IMRT (b) Simultaneous VMAT
Figure 2.4. A transverse slice dose distribution and DVHs for the rectum (blue), bladder (red) 
and the prostate PTV (green) and the DIL PTV (light blue) for the simultaneous DIL boost plans
for PI. (a) IMRT Plan, (b) VMAT plan.
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Dose (cGy) Dose (cGy)
(a) Plan 1 (b) Pian 2
Figure 2.5. A transverse slice dose distribution and DVHs for the rectum (blue), bladder (red) 
and the prostate PTV (green) and the DILPTV (light blue) for the sequential DILPTV boost 
plans for PI (high total MU/fx). (a) IMRT Plan (Plan 1), (b) VMAT plan (Plan 2).
38




DILPTV 82.3 89.9 88.1 ± 1.1
Prostate PTV - 72.6 83.4 79.0 ± 0.5
DILPTV
Plan 2
DILPTV 82.2 89.4 87.7 ± 0.9
Prostate PTV - 69.6 84.0 78.5 ±1.5
DIL PTV
Plan 5
DILPTV 81.2 89.2 87.5 ±0.8
Prostate PTV - 72.6 84.1 78.2 ± 1.3
DILPTV
Plan 6
DIL PTV 83.6 90.1 87.6 ± 0.9
Prostate PTV - 71.2 84.1 78.8 ±1.6
DIL PTV
Table 2.4. The minimum, maximum, and mean dose values for the DILPTV and the 
ProstatePTV -  DIL PTV for Plans 1, 2, 5 and 6 (from Table 2.1).
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2.3.2 IMRT and VMAT dose delivery with prostate motion
Figure 2.6 shows a comparison between measured dose and planned dose from a 
single fraction of the IMRT and VMAT simultaneous plans for different motion patterns, 
including the no-motion pattern. The no-motion pattern reported Gamma analysis for the 
two plans, with pass rate 96.2% for the IMRT plan and 98.4% for the VMAT plan. Table
2.5 lists the mean Gamma values for the six motion patterns for all investigated plans for 
PI and P2. All plans demonstrated the least sensitivity to motion Pattern 3 with the 
lowest mean Gamma values while the highest sensitivity is to motion Pattern 6. Pattern 6 
mean Gamma values exceeded 1.0 for most of the plans presented. This could be 
explained by comparing motion patterns 3 and 6. Motion Pattern 3 represents a random 
motion pattern in which the motion changes directions continuously in a random manner, 
in a sense that the total motion effect averages out. Whereas motion Pattern 6 represents 
the extreme case for prostate motion, a large shift (10 mm total displacement) that starts 
few seconds after the start of the treatment and clearly it should have the highest motion 
sensitivity. While individual Gamma values for the different motion patterns varied, the 
overall mean Gamma value of the VMAT simultaneous plan is less than the IMRT 
simultaneous plan for both patients. This overall behavior could be explained by 
considering the total MU for both plans. In general, the simultaneous IMRT plan has 
larger total MU than the VMAT simultaneous plan, thus resulting in longer delivery 
times which will make the IMRT simultaneous plan more susceptible to motion than the 
VMAT simultaneous plan. On the other hand, the overall maen Gamma value for IMRT 
boost-only 5 fractions (high MU/fraction(fx)) plans are lower than VMAT boost-only 
plans. The effect of motion for IMRT plans depends only on motion during delivery. For
40
certain patterns, abrupt motion might occur when the beam is off and the motion will not 
affect the delivery in that case, whereas for VMAT plans the beam is being delivered 
continuously and any motion occurred during delivery it will affect the final outcome. 
Another factor that can influence the sensitivity to motion for the IMRT plans is the user 
dependency. The sensitivity to intrafractional motion depends on the instances at which 
the user starts each beam during delivery. This was not a concern for the VMAT plans 
since the beam is initiated only once during delivery.
The extreme motion that is represented by Pattern 6 will create a large distance to 
agreement, which in turn led to a high mean Gamma value.
In Figure 2.7 the measured dose and the planned dose for the VMAT DILPTV 
boost in 35 fractions (total MU/fx = 134) and VMAT DIL PTV boost in 5 fractions (total 
MU/fx = 488) are compared for motion Patterns 1, 2, 3 and 4. The mean Gamma values 
in Table 2.5 demonstrated lower trend for the high total MU/fx VMAT DIL PTV boost 
plans than the low total MU/fx VMAT DIL PTV boost plans. This can be attributed to 
the fact that delivering the low total MU/fx results in too low MU per control point. 
Delivering a too low MU per control point has higher delivery uncertainty than the high 
MU per control (high total MU/fx) VMAT. [30] This became an additional source of 
uncertainty during delivery.
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Figure 2.6b Simultaneous VMAT
Figure 2.6. Measurement and calculated planar dose comparison for the no-motion pattern, 
Pattern 1, Pattern 2, Pattern 3 and Pattern 4 for PI. (a) IMRT simultaneous DILPTV boost plan,
(b) VMAT simultaneous DIL PTV boost plans.
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Pattern Pattem Pattern Pattem Pattern Pattern Mean
1 2 3 4 5 6 Gamma
PI
Plan 1 (460 total MU/fx) 0.429 0.765 0.236 0.455 0.530 0.936 0.558
Plan 2 (488 total MU/fx) 0.481 0.698 0.324 0.451 0.470 1.022 0.574
Plan 3 (52 total MU/fx) 0.672 0.731 0.603 0.720 0.689 1.045 0.743
Plan 4 (134 total MU/fx) 0.608 0.782 0.452 0.595 0.595 1.056 0.681
Plan 5 (548 total MU/fx) 0.662 1.226 0.552 0.672 0.591 1.423 0.854
Plan 6 (493 total MU/fx) 0.633 0.796 0.453 0.581 0.728 1.334 0.754
P2
Plan 1 (395 total MU/fx) 0.480 0.734 0.225 0.477 0.570 0.952 0.573
Plan 2 (477 total MU/fx) 0.513 0.802 0.322 0.543 0.486 1.171 0.639
Plan 3 (66 total MU/fx) 0.649 0.784 0.529 0.693 0.677 1.072 0.734
Plan 4 (140 total MU/fx) 0.632 0.826 0.559 0.681 0.655 0.982 0.722
Plan 5 (480 total MU/fx) 0.607 1.211 0.439 0.740 0.690 1.423 0.852
Plan 6 (486 total MU/fx) 0.670 0.851 0.459 0.613 0.760 1.443 0.799
Table 2.5. Mean Gamma values for ail motion patterns for all investigated plans for PI and P2.
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Figure 2.7. Measurement and calculated planar dose comparison for Pattern 1, Pattern 2, Pattern
3 and Pattern 4 for PI. (a) 134 total MU/fx VMAT DIL PTV boost plan, (b) 488 total MU/fx
VMAT DIL PTV boost plan.
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Figure 2.8 shows the measured dose and planned dose comparison for PI for the 
extended patterns (Patterns 5 and 6) for simultaneous IMRT and VMAT boost plans. 
Pattern 6 represents the extreme case in terms of intraprostatic motion since it involves a 
constant shift of the prostate seconds after the treatment starts. The prostate remains at 
the shifted position throughout the duration of the treatment. Table 2.5 lists the mean 
gamma values for all 6 patterns for all investigated plans for PI and P2. To investigate 
the effect of motion sensitivity relative to the phase, we compared the mean gamma 
values of Patterns 2 and 6, and Patterns 1 and 5. It is found that the mean gamma values 
for Pattern 6 are higher than those for Pattern 2 for all the plans. As for the comparison 
between Patterns 1 and 5, most of the plans posted a higher mean gamma value for 
Pattern 5 than Pattern 1. However the maximum increase was lower (13%) compared to a 
minimum increase of 16% from Pattern 1 to Pattern 6. This result is consistent with the 
difference in Patterns 1 and 5 being less than that of Patterns 2 and 6. It can also be seen 
from Table 2.5 that the mean gamma values for the sequential boost plans are less than 
those for the simultaneous plans. For sequential boost plans the field size is smaller than 




| o  s « i  - s « 2  | B®il0
-1 0 0  « 1 « 0 40 -20 0
Y (« n )
20 40
Abso$ i 0 o t* v £ 5  
CAX 23328 236 80
US**
-352 1 45 0  00
S e tlP o i
X /Y w n
Oose













i o  Sh i ED (B G
-1 0 0  -80  -60 4 0  -2 0  0  20 
Y(«W1)





i t l  m
232 74 236 80  4 05 
21654 24261 -2607 
23274 23680 -4 05
-1 67 00 0
•1075 0  00 -5/15 -5/15 















Figure 2.8. Measurement and calculated planar dose comparison for Pattern 5, and Pattern 6 for
PI. (a) IMRT simultaneous DILPTV boost plan, (b) VMAT simultaneous DILPTV boost plan.
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Table 2.6 lists the rrms values inside the DILGTV for each pattern and the 
average rrms value over six patterns for different plans investigated for PI. Pattern 6 for 
all the plans had the highest rrms values with the highest values being 18.4% for the 
VMAT DILPTV boost plan (134 total MU/fx). On average, the VMAT simultaneous 
plan showed the lowest values of the rrms. This could be explained by considering the 
fact that for the VMAT simultaneous plans the delivery time is less than that for the 
IMRT simultaneous plan which makes the interplay effect between the phantom motion 
and the MLC motion during delivery more prominent for the IMRT plan. Table 2.7 lists 
the percent of measured points receiving at least 90% of the prescribed dose inside the 
DIL GTV. For the simultaneous plans, all but motion Pattern 6 had all the measured 
points receiving at least 90% of the prescribed dose. The delivery uncertainty in the 
VMAT DIL PTV boost plan (134 total MU/fx) is evident since only Patterns 1 and 4 
managed to have all the measured points receiving at least 90% of the prescribed dose.
Figure 2.9 shows a measurement and calculated planar dose comparison for the 
C35-1 and C35-2 probability weighted combinations for PI for the simultaneous IMRT 
boost and VMAT boost plans. Table 2.8 lists the mean gamma values for the probability 
weighted combinations for all the investigated plans for both patients. The mean gamma 
values for C35-1 are higher than the ones for C35-2 for all plans. As expected, the plans 
have less delivery errors when most of the fractions with motion are dominated by the 
random motion pattern. The VMAT DIL PTV high total MU/fx boost plan is less 
sensitive to motion than the low total MU/fx plan for both patients. This result for the 35 
fraction simulations are consistent with the results obtained from the single fraction 
comparisons presented in Table 2.5 and Figure 2.7. It is also expected for the average
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values (C5-average and C35-average) to fall between the two extreme combinations. The 
only exception was for Plan 5 for both patients. The reason for that is the inclusion of 
Pattern 2 in the average combination and not in the extreme combinations. The average 
gamma value for Pattern 2 for this particular plan is high and that will increase its weight 
when it is included in the average value for the whole combination.
Pattern Pattern Pattern Pattern Pattern Pattern Ave.
i 2 3 4 5 6 rrms
Plan 1 (460 total MU/fx) 3.1% 6.4% 2.2% 6.6% 5.0% 11.5% 5.8%
Plan 2 (488 total MU/fx) 2.9% 3.9% 2.0% 2.4% 4.4% 12.4% 4.7%
Plan 3 (52 total MU/fx) 3.8% 4.9% 2.5% 5.0% 2.2% 8.8% 4.5%
Plan 4 (134 total MU/fx) 4.5% 5.8% 1.3% 7.4% 6.1% 18.4% 7.2%
Plan 5 (548 total MU/fx) 1.4% 1.9% 1.6% 1.9% 1.4% 4.7% 2.1%
Plan 6 (493 total MU/fx) 1.4% 1.3% 0.4% 1.6% 1.5% 3.6% 1.6%
Table 2.6. The percent rrms values inside DIL GTV and the average rrms value for the different 
motion patterns for the different plans investigated for PI.
Pattern Pattern Pattern Pattern Pattern Pattern Ave.
1 2 3 4 5 6 percent
Plan 1 (460 total MU/fx) 100% 92.3% 76.9% 100% 100% 69.2% 89.7%
Plan 2 (488 total MU/fx) 100% 84.6% 100% 100% 100% 76.9% 93.6%
Plan 3 (52 total MU/fx) 100% 100% 100% 100% 100% 84.6% 97.4%
Plan 4 (134 total MU/fx) 100% 76.9% 92.3% 100% 92.3% 76.9% 89.7%
Plan 5 (548 total MU/fx) 100% 100% 100% 100% 100% 76.9% 96.2%
Plan 6 (493 total MU/fx) 100% 100% 100% 100% 100% 76.9% 96.2%
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Figure 2.9. Measurement and calculated planar dose comparison for the different probability
weighted combinations for PI. (a) IMRT simultaneous D1L PTV boost plan, (b) VMAT




Plan 1 (460 total MU/fx) 0.423 0.264 0.366
Plan 2 (488 total MU/fx) 0.494 0.321 0.397
C35-1 C35-2 C35-3 C35-4 C35-
average
Plan 3 (52 total MU/fx) 0.588 0.518 0.317 0.319 0.552
Plan 4 (134 total MU/fx) 0.597 0.453 0.393 0.418 0.515
Plan 5 (548 total MU/fx) 0.630 0.493 0.451 0.473 0.640
Plan 6 (493 total MU/fx) 0.609 0.470 0.402 0.416 0.547
P2
C5-1 C5-2 C5-average
Plan 1 (396 total MU/fx) 0.425 0.266 0.366
Plan 2 (477 total MU/fx) 0.508 0.312 0.425
C35-1 C35-2 C35-4 C35-4 C35-
average
Plan 3 (66 total MU/fx) 0.564 0.487 0.500 0.515 0.557
Plan 4 (140 total MU/fx) 0.615 0.521 0.397 0.410 0.568
Plan 5 (480 total MU/fx) 0.513 0.411 0.530 0.561 0.619
Plan 6 (486 total MU/fx) 0.621 0.477 0.501 0.531 0.563
Table 2.8. Mean Gamma values for different probability weighted treatment courses for all
investigated plans for PI and P2.
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CHAPTER 3
Discussion, Limitations and Future Work, Conclusions
3.1 Discussion
It is clear from Figure 2.3 that dose escalation to the whole prostate will likely 
compromise the dose received by the bladder and rectum. This observation provided the 
motivation to test the feasibility of escalating the dose to a DIL through different 
treatment techniques.
Both sequential and simultaneous IMRT and VMAT plans succeeded in 
escalating the dose to the DIL PTV while keeping the bladder and rectum doses below 
normal tissue tolerances. However, dose escalation to the entire prostate to 86 Gy would 
exceed the normal tissue tolerances for the two patients.
We succeeded in delivering all the generated plans. It is clear for all the 
investigated plans that the treatment is less sensitive to random prostate motion than if the 
motion was a large sudden shift in a certain direction. In particular, VMAT sequential 
boost plans showed different sensitivities to motion depending on the total MU/ix 
delivered. VMAT has less total MU than IMRT, hence less beam on time, and generally 
less sensitive to patient motion. On the other hand, the low total MU/fx VMAT boost 
plan showed more sensitivity to motion than high total MU/fx plan for all motion 
patterns. Delivering too low MU per control point introduced an extra source of 
uncertainty. In the low MU VMAT plans for PI and P2, their MU per degree were 0.37 
and 0.39 respectively, both less than 0.5 MU per degree. This is a reason for not 
considering <0.5 MU per degree VMAT boost phase for treatment.
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Based on the rrms evaluations, the loss of dose due to motion inside the DIL is 
least prominent for the VMAT simultaneous plan. In sequential plans, if the delivery of 
each plan was preceded by imaging and adjusting the patient then the motion uncertainty 
of the whole prostate will not provide an additional dose difference to the DIL when the 
whole prostate plan is delivered. This is because the field size is larger for the whole 
prostate plan, the DIL PTV will totally lie within the prostate PTV and it will receive 
the full prescribed dose.
The rrms results shown in Table 2.6 represent values for specific patterns. No 
statistical significance can be drawn from the differences between the average rrms 
values for the different plans. However, more analysis should be performed when 
considering different phases of the patterns to include a larger database from which one 
can analyze statistically.
The probability weighted combinations of measurements were introduced to 
investigate more realistically the effect of motion on the whole course of treatment. Two 
combinations were chosen for comparison for all the investigated plans, one that had 5 
fractions of the severe motion pattern (Pattern 6) and one had 5 fractions of random 
motion pattern (Pattern 3). As expected the combination dominated by Pattern 3 was less 
sensitive to the overall motion than the combination dominated by Pattern 6.
3.2 Limitations and Future Work
One of the limitations of this work was the fact that the DIL is hypothetical and 
not identified by functional imaging. A future step is to apply this study to patient CT 
scan with an identified DIL. The DIL chosen for this study was located at the posterior-
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inferior-left side of the prostate; this limited the study to one DIL location only. 
Inspecting the effect of the location of the DIL on the intrafractional motion is another 
aim for future work. It is also of interest to repeat the study on multiple DILs and inspect 
the limit to which a boost could be delivered without increasing the toxicity to the OARs 
beyond their normal tissue tolerances. The motion platform used in this work was not 
designed to reproduce typical motion of the prostate and a specialized motion platform 
that can more easily simulate the prostate intrafractional motion should be designed and 
built.
3.3 Conclusions
In conclusion, it is possible to escalate the dose to a DIL without exceeding 
normal tissue tolerances. Random motion of the prostate during treatment proved to be 
the least motion sensitive pattern. Sudden constant shifts in the prostate during the 
treatment demonstrated high degree of dose delivery errors. The impact of motion on 
dose delivery is sensitive to the motion phase relative to the delivery time especially if 
extreme motion take place at the start or end of treatment. In addition to motion 
uncertainty, VMAT plans with low MU per control point (e.g. less than 0.5 MU per 
degree) add an extra source of dose delivery uncertainty as we have seen in boost plans 
that were delivered over 35 fractions. The effect of motion uncertainty on the whole 
treatment course depends on the motion patterns taking place during treatment, this was 
evident when different combinations of treatment courses were compared. In conclusion, 
dose escalation to DIL using simultaneous boost plans with 7 mm PTV margin is feasible
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in the presence of intra fractional motion, as long as the severe motion do not exceed 5 
out of 35 fractions.
